Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership

Published: Monday, August 27, 2012
Last Updated: Sunday, August 26, 2012
Bookmark and Share
Agreement for diagnostic test development for pathogen detection.

Affymetrix, Inc. and PathGEN Dx Pte. Ltd. have announced that they have signed a Powered by Affymetrix™ (PbA) Program agreement.

Under this PbA agreement, PathGEN Dx will develop an in-vitro diagnostic kit for comprehensive pathogen detection using their PathGEN® PathChip and is based on a patented, efficient, and accurate microarray-based protocol and analysis method.

The kit will be comprised of PathGEN Dx’s proprietary reagents, an automated software package, and a contract manufactured GeneChip® microarray from Affymetrix.

It will detect the presence of more than 70,000 viral and bacterial genomes from a wide variety of human samples, annotate the genomic information, and identify co-infecting pathogens.

Dr. Martin Hibberd, PathGEN Dx Co-Founder, said, “This will be the start of our development plan for a diagnostic microarray that we feel will ultimately help medical researchers and surveillance investigators identify the full range of viruses and bacteria in their samples.”

“We are very pleased to have PathGEN Dx join the Affymetrix’ PbA Program. This adds significantly to our PbA Program in which we help partners to develop novel molecular diagnostic tests that will potentially provide solutions for directing proper treatment for patients,” said Roger Schaller, Sr. Director of Global Business Development for Clinical Applications at Affymetrix.

“We are very proud that PathGEN Dx, the first spin-off from GIS, has achieved this collaboration that will significantly advance their reach to the clinical diagnostics global market. The journey first began in 2004 as a project in GIS, and then funded by Exploit Technologies in 2008 to clinically validate, productize, and develop the business strategy. This is an exciting next phase in PathGEN DX’s entrepreneurial journey and we look forward to greater success,” said Mr. Philip Lim, CEO of Exploit Technologies, A*STAR’s technology transfer arm.

“The Genome Institute of Singapore is pleased to support PathGEN Dx and look forward to incubating more startups in the future,” said Prof. Ng Huck Hui, Acting Executive Director of GIS.

This PbA Program agreement also provides PathGEN Dx access to Affymetrix’ international distribution network.

Dr. Christopher Wong, Founder of PathGEN Dx, added “We are pleased to join the ranks of other PbA Program partners, such as Roche Diagnostics and Pathwork Diagnostics in adopting the Affymetrix technology in our IVD product development program.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquires Affymetrix
Thermo Fisher Scientific and Affymetrix, has announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion.
Friday, April 01, 2016
Groupe Grimaud Chooses Affymetrix Genotyping Arrays
Affymetrix, Inc. has announced that one of the world’s largest producers of breeding chickens – Roussay, France-based Groupe Grimaud – will use the Axiom® genotyping platform from Affymetrix in its genomic selection and poultry breeding program.
Thursday, February 25, 2016
Bio-Genesys, Affymetrix Partner
Partnership to offer animal genomic testing services to professional farming operations.
Wednesday, January 13, 2016
Thermo Fisher Scientific to Acquire Affymetrix
Strengthens leadership in biosciences and genetic analysis.
Monday, January 11, 2016
Affymetrix, Reveal Biosciences Partner
Partnership agreement to offer RNA ISH tissue staining, imaging, and image analysis services.
Thursday, December 03, 2015
Affymetrix and Athletigen Partner
Partnership agreement to advance genetics in human athletic performance.
Thursday, October 29, 2015
Affymetrix and Luminex Announce Distribution Agreement
Agreement for multiplexed assay instrument platform.
Friday, October 16, 2015
Green Super Rice Project Selects Affymetrix Genotyping Platform for Developing New Rice Varieties
The Green Super Rice (GSR) project includes building a highly efficient genotyping platform for the large-scale molecular breeding activities within the international rice research community.
Tuesday, September 22, 2015
Affymetrix, BioRealm, RUCDR Ally
Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.
Wednesday, July 08, 2015
Affymetrix Acquires Assets of Eureka Genomics
Aquisition will enable provision of high throughput and economical crop and animal genotyping.
Thursday, May 14, 2015
CollabRx, Affymetrix To Develop Analytical Tools For Integrated Clinical Cancer Panels
The overall objective of the partnership is to provide scientific knowledge for biomarker CNV profiles in cancer.
Wednesday, April 16, 2014
University of Bristol Collaborates with Affymetrix on Genotyping Arrays
Results from the array presented at the 2014 Plant and Animal Genome conference.
Wednesday, January 15, 2014
Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data
Generated from FFPE solid tumor samples for accelerating cancer translational research.
Thursday, April 11, 2013
Ingenuity Systems and Affymetrix Partner
Companies collaborate to eliminate microarray expression analysis bottleneck.
Monday, April 08, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!